CT041, an auto anti-CLDN18.2 CAR-T has shown promising activity, with an ORR (across three different trials) of ~60%, in patients with gastric, gastro-esophageal junction and pancreatic cancers. However, mPFS, mDOR and mOS need improving, which is where that could come in. I know they already add nab-paclitaxel as part of the preconditioning regimen.